

JCWSCS 0 5 NOV 2004

FOLEY

FOLEY & LARDNER LLP
ATTORNEYS AT LAW

1530 PAGE MILL ROAD
PALO ALTO, CA 94304-1125
TELEPHONE: 650.856.3700
FACSIMILE: 650.856.3710
WWW.FOLEY.COM

FACSIMILE TRANSMISSION

Total # of Pages 8 (including this page)

TO:	PHONE #:	FAX #:
Initial Patent Examiner's Filing Receipt Corrections USPTO		1-703-746-9195

From : Gerald F. Swiss
Email Address : gswiss@foley.com
Sender's Direct Dial : 650.856.3703
Date : November 4, 2004
Client/Matter No : 342837-2201
User ID No : 4244

MESSAGE:

Please see attached request for Correct Filing Receipt and Corrected Customer ID Number.

If there are any problems with this transmission or if you have not received all of the pages, please call 1-650-739-0139.

Operator:	Time Sent:	Return Original To: Gerald F. Swiss
-----------	------------	--

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrei W. KONRADI et al.
Title: PHENYLALANINE DERIVATIVES AS
ALPHA 4 INTEGRIN INHIBITORS
Appl. No.: 10/735,499
Filing Date: December 12, 2003
Examiner: Not Yet Assigned
Art Unit: 1614

<p>CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facsimile transmitted to the Initial Patent Examination's Filing Receipt Corrections, at facsimile number 703-748-9195 at the United States Patent and Trademark Office, Alexandria, Virginia on the date below.</p> <p><u>Kristen Cumming</u> (Printed Name)</p> <p><u>Kristen Cumming</u> (Signature)</p> <p><u>November 4, 2004</u></p>
--

**TRANSMITTAL FOR CORRECTED FILING RECEIPT AND CORRECTED
CUSTOMER NUMBER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a Request for Corrected Filing Receipt and Corrected Customer Number in the above-identified application.

- ☒ Copy of marked-up Filing Receipt.
- ☐ Return Receipt Postcard.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date

11-4-04

FOLEY & LARDNER LLP
1530 Page Mill Road
Palo Alto, CA 94304
Palo Alto, California 94306
Telephone: (650) 251-1103
Facsimile: (650) 856-3710


By

Gerald F. Swiss

Gerald F. Swiss
Attorney for Applicant
Registration No. 30,113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrei W. KONRADI et al.
Title: PHENYLALANINE
DERIVATIVES AS ALPHA 4
INTEGRIN INHIBITORS
Appl. No.: 10/735,499
Filing Date: December 12, 2003
Examiner: Not Yet Assigned
Art Unit: 1614



REQUEST FOR CORRECTED FILING RECEIPT & CORRECTED CUSTOMER NUMBER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attn: Application Processing Division, Customer Correction Branch

Sir:

Attached is a copy of the official Filing Receipt received from the PTO in the above-referenced application.

There is an error with respect to the Customer ID Number. The Customer ID number should be 38706 and the attorney/law firm should read:

Gerald F. Swiss
Foley & Lardner LLP
1530 Page Mill Road
Palo Alto, CA 94304

Please note, that the correspondence for the above-referenced patent application have been sent to the wrong customer. Please correct and send all correspondence to the customer number as indicated.

The corrections are not due to any error by Applicant and, accordingly, no fee is due.
Issuance of a corrected Filing Receipt is respectfully requested.

Respectfully submitted,

Date 11-4-04

By Gerald F. Swiss

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 251-1103
Facsimile: (650) 856-3710

Gerald F. Swiss
Attorney for Applicant
Registration No. 30,113

NOV. 2. 2004 3:00PM

AVENTIS US PAT DEPT **BEST AVAILABLE COPY** pa. 2/42

UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 107
 Alexandria, Virginia 22313-1070

APPL NO.	FILING OR 371 (a) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	POT CLMS	IND CLMS
10/735,499	12/12/2003	1624	770	42837-20027.10			3

CONFIRMATION NO. 1691

CORRECTED FILING RECEIPT

 (PRINTED FILE NO. AND FILING DATE ARE NOT VALID FOR FILING PURPOSES)
 0000000013823133

885487-38706
 ROSS J. OEHLE Gerald F. SWISS
 AVENTIS PHARMACEUTICALS INC. Foley & Lardner LLP
 ROUTE 202-206 1530 Page Mill Road
 MAIL CODE: D383A Palo Alto, CA 94304
 BRIDGEWATER, NJ 08807

Date Mailed: 09/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andrei W. Konradi, San Francisco, CA;
 Michael A. Pleiss, Sunnyvale, CA;
 Eugene D. Thorsett, Half Moon Bay, CA;
 Susan Ashwell, Lexington, MA;
 Gregory S. Weismaker, Jackson, NJ;
 Anthony Kreft, Langhorne, PA;
 Dimitrios Sarantakis, Newtown, PA;
 Darren B. Dressen, San Francisco, CA;
 Francine S. Grant, San Carlos, CA;
 Christopher Sernko, Fremont, CA;
 Ying-Zi Xu, Palo Alto, CA;

Assignment For Published Patent Application

Elian Pharmaceuticals, Inc.
 Wyeth

Power of Attorney: The patent practitioners associated with Customer Number 005487.

Domestic Priority data as claimed by applicant

This application is a DIV of 08/910,685 07/20/2001 PAT 6,669,781
 which claims benefit of 60/220,134 07/21/2000

Foreign Applications

If Required, Foreign Filing License Granted: 03/23/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/735,499

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

Phenylalanine derivatives as alpha 4 integrin inhibitors

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

